Fig. 5

Integrin CD11b agonism suppresses tumor growth and promotes survival in mouse models of cancer. a Structure of LA1. b Adhesion of macrophages in the absence or presence of Ca²⁺Mg²⁺ (white bars) Mn²⁺ (black bars), LA1 (cyan bars) or LA1+ neutralizing anti-CD11b (gray bars) (n = 3). c Relative mRNA expression of Let7a, Il16, or Pdgfb in control (black bars) and LA1 (cyan bars)-treated macrophages (n = 3). d Tumor weights 16 days after implantation of LLC cells mixed 1:1 with control-treated (dots), DMSO-treated (triangles) or LA1-treated (diamonds) tumor-derived macrophages (n = 8). e Tumor growth curves as represented by volumes from d: control (black line), vehicle (gray line) and LA1 (red line) (n = 8). f Effect of LA1 on in vitro proliferation of LLC cells and macrophages (n = 4). g Tumor volumes of orthotopic CL66 breast tumors treated with vehicle (black line), Taxol (gray line), LA1 (dark blue line) or LA1 + Taxol (cyan line) (n = 10–15). h Tumor volumes of orthotopic CL66 tumors treated with vehicle (black line), irradiation (gray line) (IR, 20 Gy), LA1 (dark blue line) (2 mg/kg), or LA1 + IR (cyan line) (n = 9). i Tumor volumes of orthotopic human MDA-MB-231 mammary xenografts treated with vehicle (control, black line), Taxol (gray line), or LA1 (blue line) (n = 7). j, k Mean LLC subcutaneous tumor volumes of j WT (black line) and k Itgam-/- (cyan line) mice treated with and without LA1 (n = 6). l Images and quantification of SMA/CD31 expression in blood vessels of control (black bars) and LA1 treated (cyan bars) animals from g, i, and j. Bar on micrographs indicates 50 µm. m Schematic depicting role of CD11b activation in the control of immune stimulation. Error bars indicate sem. “n” indicates biological replicates. *p < 0.5 indicates statistical significance by Student’s t-test c, f; Anova with Tukey post-hoc testing for d–e; unpaired t-test g, i; Mann–Whitney t-test b, j–l; Wilcox test 5 h. Source data are provided as a Source Data file